Predicting colorectal cancer survival by combined c-reactive protein and tumor immune score
We evaluated the joint relationship of post-operative C-reactive protein (poCRP) and a tumor immune-cell-score (IS) with overall survival (OS) and CRC-specific survival (CSS) in 680 colorectal cancer (CRC) patients recruited in Germany. CRP was assessed post-surgery while IS was derived from CD3 + /...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
25 November 2025
|
| In: |
npj precision oncology
Year: 2025, Jahrgang: 9, Heft: 1, Pages: 1-7 |
| ISSN: | 2397-768X |
| DOI: | 10.1038/s41698-025-01192-1 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41698-025-01192-1 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41698-025-01192-1 
|
| Verfasserangaben: | Tafirenyika Gwenzi, Durgesh Wankhede, Tanwei Yuan, Megha Bhardwaj, Petra Schrotz-King, Sophie C. Anker, Ben Schöttker, Michael Hoffmeister and Hermann Brenner |
| Zusammenfassung: | We evaluated the joint relationship of post-operative C-reactive protein (poCRP) and a tumor immune-cell-score (IS) with overall survival (OS) and CRC-specific survival (CSS) in 680 colorectal cancer (CRC) patients recruited in Germany. CRP was assessed post-surgery while IS was derived from CD3 + /CD8+ cell densities in tumor tissue. Patients were categorized into four C-Reactive protein-Immune cell Score (CRIS) groups: CRIS-1 (CRP-low/IS-high), CRIS-2 (CRP-low/IS-low), CRIS-3 (CRP-high/IS-high), and CRIS-4 (CRP-high/IS-low). Associations of CRIS with survival were assessed using Cox regression, and quantified by hazard ratios with 95% confidence intervals (HR, 95%CI). Subgroup analysis by presence of non-metastatic disease and time of blood draw in relation to adjuvant chemotherapy were conducted. After a median follow-up of 9.6 (IQR, 4.6-14.6) years, 214 (31.5%) patients died, 140 (20.6%) from CRC. Patients in CRIS-4 category had worse prognosis compared to CRIS-1 category [HR(95%CI): 2.01 (1.32-3.08) and 2.60 (1.57-4.32) for OS and CSS, respectively]. These associations were stronger for non-metastatic disease (OSHR = 2.45, CSSHR = 4.49), as well as for patients with blood collected after adjuvant chemotherapy (OSHR = 4.17, CSSHR = 6.62). Integrating post-operative systemic inflammation and tumor immune characteristics may improve prognostic stratification of patients receiving adjuvant chemotherapy for non-metastatic CRC. |
|---|---|
| Beschreibung: | Gesehen am 03.03.2026 |
| Beschreibung: | Online Resource |
| ISSN: | 2397-768X |
| DOI: | 10.1038/s41698-025-01192-1 |